Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have been given an average rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $33.25.

BCYC has been the topic of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. JMP Securities lowered their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $33.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. B. Riley lowered their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Stephens reissued an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd.

Bicycle Therapeutics Trading Down 5.5 %

BCYC stock opened at $12.66 on Tuesday. The stock has a market capitalization of $874.17 million, a PE ratio of -3.85 and a beta of 0.93. Bicycle Therapeutics has a 12-month low of $12.17 and a 12-month high of $28.67. The stock’s 50 day simple moving average is $15.68 and its 200 day simple moving average is $20.82.

Insider Transactions at Bicycle Therapeutics

In related news, Director Bros. Advisors Lp Baker acquired 985,397 shares of the company’s stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the acquisition, the director now directly owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at $483,141.51. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,933 shares of company stock worth $549,501 in the last three months. Corporate insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Assetmark Inc. bought a new stake in Bicycle Therapeutics in the third quarter worth about $34,000. GAMMA Investing LLC lifted its stake in Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after purchasing an additional 1,038 shares during the last quarter. Avior Wealth Management LLC bought a new stake in Bicycle Therapeutics in the fourth quarter worth about $57,000. China Universal Asset Management Co. Ltd. lifted its stake in Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after purchasing an additional 2,191 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares during the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.